Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by First Hawaiian Bank

First Hawaiian Bank decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,624 shares of the biopharmaceutical company’s stock after selling 36 shares during the quarter. First Hawaiian Bank’s holdings in Regeneron Pharmaceuticals were worth $2,758,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. West Paces Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares in the last quarter. Criterion Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $37,000. Finally, BOK Financial Private Wealth Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $37,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now directly owns 466,877 shares in the company, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,074 shares of company stock valued at $64,546,123. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Down 1.0 %

REGN traded down $10.91 during midday trading on Monday, hitting $1,071.28. 611,139 shares of the company’s stock traded hands, compared to its average volume of 471,453. The company has a market cap of $118.04 billion, a PE ratio of 31.77, a price-to-earnings-growth ratio of 2.34 and a beta of 0.13. The stock’s fifty day simple moving average is $1,043.43 and its 200-day simple moving average is $983.16. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.96 and a quick ratio of 4.51. Regeneron Pharmaceuticals, Inc. has a one year low of $765.28 and a one year high of $1,115.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the firm earned $8.79 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

REGN has been the subject of a number of analyst reports. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Piper Sandler raised their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Royal Bank of Canada raised their price target on shares of Regeneron Pharmaceuticals from $1,232.00 to $1,240.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,097.05.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.